This is relevant because it is now established that patients with p16–negative/HPV-positive or p16-positive/HPV–negative disease display a significantly worse prognosis than patients with p16-positive/HPV-positive oropharyngeal cancer, and a significantly better prognosis than patients with p16–negative/HPV-negative oropharyngeal cancer [12]. This evidence concerns the gene CDKN2A and oropharynx cancer.